Orna’s ORN-252 is a clinical trial-ready CAR-T therapy that targets CD19, a critical cell surface protein to treat B ...

Feb 9 (Reuters) - Eli Lilly will buy therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said ...

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to ...

Eli Lilly to acquire Orna Therapeutics for up to $2.4B, boosting in vivo CAR-T and circular RNA therapies for autoimmune disease.

US pharma major Eli Lilly today announced entry into a definitive agreement to acquire Orna Therapeutics, marking its second ...

Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the planned acquisition of Orna Therapeutics and a new large-scale strategic ...

Deep within our nerve cells, a molecule is at work that has no beginning and no end. Instead of a straight chain, as is common for most RNA strands, it forms a closed loop. Known as circular RNAs ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, ...

Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negotiate licensing agreement Altamira Therapeutics Ltd.